Designing drugs that combat kidney damage

Expert Opinion on Drug Discovery

Volumn 10, Issue 5, 2015, Pages 541-556

  Ramos, Adrián M ^a,b,c,d   González Guerrero, Cristian ^a   Sanz, Ana ^a   Sanchez Niño, María Dolores ^e   Rodríguez Osorio, Laura ^a   Martín Cleary, Catalina ^a   Fernández Fernández, Beatriz ^a   Ruiz Ortega, Marta ^a,b,c   Ortiz, Alberto ^b,c,d  

^a 28400 Madrid   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Section of Nephrology   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Clinical trials; Drug discovery; Kidney damage; Nanomedicine; Nephrology

Indexed keywords

ANTIPROTEINURIC AGENT; CCX140; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROPOIETIN; IMMUNOSUPPRESSIVE AGENT; IRON CHELATING AGENT; PROTEIN INHIBITOR; QPI 1002; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DEATH; CHRONIC KIDNEY DISEASE; DRUG ACCUMULATION; DRUG DESIGN; DRUG REPOSITIONING; DRUG TARGETING; HUMAN; INFLAMMATION; KIDNEY FIBROSIS; KIDNEY INJURY; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; REGENERATION; REVIEW; ACUTE KIDNEY INJURY; ANIMAL; DRUG EFFECTS; FIBROSIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ACUTE KIDNEY INJURY; ANIMALS; CELL DEATH; DRUG DESIGN; DRUG REPOSITIONING; FIBROSIS; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; NANOMEDICINE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84928350591     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1033394     Document Type: Review

References (164)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385(9963):117-71
2. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet 2012;380(9843):756-66
3. Fine J, Seligman A, Frank HA. Peritoneal dialysis for acute renal failure. NY Med 1949;5(10):16-20
4. Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med 2010;363(19):1833-45
5. Dharnidharka VR, Fiorina P, Harmon WE. Kidney transplantation in children. N Engl J Med 2014;371(6):549-58
6. Ortiz A. Translational Nephrology: what translational research is and a bird's-eye view on translational research in Nephrology. Clin Kidney J 2015;8(1):14-22
7. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 2004;15(2):411-19
8. KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150
9. Ortiz A, Covic A, Fliser D, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014;383(9931):1831-43
10. Sanz AB, Sanchez-Niño MD, Martín-Cleary C, et al. Progress in the development of animal models of acute kidney injury and its impact on drug discovery. Expert Opin Drug Discov 2013;8(7):879-95
11. Ortiz A, Cianciaruso B, Cizmarik M, et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 2010;25(3):769-75
12. Mischak H, Ioannidis JP, Argiles A, et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 2012;42(9):1027-36
13. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, et al. Therapeutic approaches to diabetic nephropathy beyond the RAS. Nat Rev Nephrol 2014;10(6):325-46
14. Dolman ME, Harmsen S, Pieters EH, et al. Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. Int J Nanomedicine 2012;7:417-33
15. Poosti F, Yazdani S, Dolman ME, et al. Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection. Eur J Pharmacol 2012;694(1-3):111-19
16. Stokman G, Qin Y, Booij TH, et al. Epac-Rap signaling reduces oxidative stress in the tubular epithelium. J Am Soc Nephrol 2014;25(7):1474-85
17. Falke LL, van Vuuren SH, Kazazi-Hyseni F, et al. Local therapeutic efficacy with reduced systemic side effects by rapamycin-loaded subcapsular microspheres. Biomaterials 2015;42:151-60
18. Linkermann A, Bräsen JH, Himmerkus N, et al. Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int 2012;81(8):751-61
19. Linkermann A, Bräsen JH, Darding M, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA 2013;110(29):12024-9
20. Linkermann A, Chen G, Dong G, et al. Regulated cell death in AKI. J Am Soc Nephrol 2014;25(12):2689-701
21. Sanz AB, Santamaría B, Ruiz-Ortega M, et al. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 2008;19(9):1634-42
22. Santamaría B, Benito-Martin A, Ucero AC, et al. A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury. PLoS One 2009;4(8):e6634
23. Ucero AC, Berzal S, Ocaña-Salceda C, et al. A polymeric nanomedicine diminishes inflammatory events in renal tubular cells. PLoS One 2013;8(1):e51992
24. Orzáez M, Sancho M, Marchán S, et al. Apaf-1 inhibitors protect from unwanted cell death in in vivo models of kidney ischemia and chemotherapy induced ototoxicity. PLoS One 2014;9(10):e110979
25. Linkermann A, Stockwell BR, Krautwald S, et al. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol 2014;14(11):759-67
26. Skouta R, Dixon SJ, Wang J, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc 2014;136(12):4551-6
27. Linkermann A, Skouta R, Himmerkus N, et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci USA 2014;111(47):16836-41
28. Sanchez-Niño MD, Sanz AB, Lorz C, et al. BASP1 promotes apoptosis in diabetic nephropathy. J Am Soc Nephro 2010;21(4):610-21
29. Moreno JA, Moreno S, Rubio-Navarro A, et al. Role of chemokines in proteinuric kidney disorders. Expert Rev Mol Med 2014;16:e3
30. Ruiz-Ortega M, Ortiz A, Ramos AM. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease. Curr Opin Nephrol Hypertens 2014;23(1):93-100
31. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361(9):888-98
32. Turner JE, Paust HJ, Steinmetz OM, Panzer U. The Th17 immune response in renal inflammation. Kidney Int 2010;77(12):1070-5
33. Kitching AR, Holdsworth SR. The emergence of TH17 cells as effectors of renal injury. J Am Soc Nephrol 2011;22(2):235-8
34. Rodrigues-Díez R, Rodrigues-Díez RR, Rayego-Mateos S, et al. The C-terminal module IV of connective tissue growth factor is a novel immune modulator of theTh17 response. Lab Invest 2013;93(7):812-24
35. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441(7090):235-8
36. Mahajan D, Wang Y, Qin X, et al. CD4 +CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J Am Soc Nephrol 2006;17(10):2731-41
37. Kanellakis P, Dinh TN, Agrotis A, et al. CD4+CD25+Foxp3+ regulatory T cells suppress cardiac fibrosis in the hypertensive heart. J Hypertens 2011;29(9):1820-8
38. Rodrigues-Díez R, Aroeira LS, Orejudo M, et al. IL-17A is a novel player in dialysis-induced peritoneal damage. Kidney Int 2014;86(2):303-15
39. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014;371(4):326-38
40. Kanamori H, Matsubara T, Mima A, et al. Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 2007;360(4):772-7
41. Kang YS, Lee MH, Song HK, et al. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int 2010;78(9):883-94
42. Sullivan TJ, Miao Z, Zhao BN, et al. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism 2013;62(11):1623-32
43. Sullivan T, Miao Z, Dairaghi DJ, et al. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knock-in mice. Am J Physiol Renal Physiol 2013;305(9):F1288-97
44. ChemoCentryx announces positive results in phase II diabetic nephropathy trial with CCR2 inhibitor CCX140. Available form: http://ir.chemocentryx.com/releasedetail.cfm?ReleaseID=887402 [Last accessed 20 March 2015]
45. Sanz AB, Izquierdo MC, Sanchez-Niño MD, et al. TWEAK and the progression of renal disease: clinical translation. Nephrol Dial Transplant 2014;29(Suppl 1):i54-62
46. Schwartz N, Su L, Burkly LC, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006;27(4):242-50
47. Xia Y, Campbell SR, Broder A, et al. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol 2012;145(2):108-21
48. Xia Y, Herlitz LC, Gindea S, et al. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J Am Soc Nephrol 2014. [Epub ahead of print]
49. BIIB023 (Anti-TWEAK) in Subjects with Rheumatoid Arthritis. Available from: https://clinicaltrials.gov/ct2/results?term=NCT00771329&Search=Search [Last accessed 20 March 2015]
50. BIIB023 long-term extension study in subjects with lupus nephritis. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01930890&Search=Search [Last accessed 20 March 2015]
51. Sanz AB, Justo P, Sanchez-Niño MD, et al. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 2008;19(4):695-703
52. Sanz AB, Sanchez-Niño MD, Izquierdo MC, et al. Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med 2009;13(9B):3329-42
53. Sanchez-Niño MD, Poveda J, Sanz AB, et al. Fn14 in podocytes and proteinuric kidney disease. Biochim Biophys Acta 2013;1832(12):2232-43
54. Ucero AC, Benito-Martin A, Fuentes-Calvo I, et al. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim Biophys Acta 2013;1832(10):1744-55
55. Martín P, Mora I, Cortes MA, et al. Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis. Am J Physiol Renal Physiol 2014;307(1):F75-85
56. Liu H, Jia Z, Soodvilai S, et al. Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion injury. Am J Physiol Renal Physiol 2008;295(4):F942-9
57. Wang H, Liu H, Jia Z, et al. Nitro-oleic acid protects against endotoxin-induced endotoxemia and multiorgan injury in mice. Am J Physiol Renal Physiol 2010;298(3):F754-62
58. Liu S, Jia Z, Zhou L, et al. Nitro-oleic acid protects against adriamycin-induced nephropathy in mice. Am J Physiol Renal Physiol 2013;305(11):F1533-41
59. Liu Y, Jia Z, Liu S, et al. Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice. Am J Physiol Renal Physiol 2013;305(11):F1555-62
60. Open-label study of safety, tolerability and PK of IV CXA-10 emulsion in subjects with stage 3 and 4 chronic kidney injury. Available from: https://clinicaltrials.gov/ct2/results?term=NCT02248501&Search=Search [Last accessed 20 March 2015]
61. Oral CXA-10 study in healthy volunteers. Available from: https://clinicaltrials.gov/ct2/results?term=NCT02313064&Search=Search [Last accessed 20 March 2015]
62. Peters E, Heemskerk S, Masereeuw R, et al. Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically ill patients. Am J Kidney Dis 2014;63(6):1038-48
63. A safety, tolerability, efficacy and QoL study of human recAP in the treatment of patients with SA-AKI. Available from: https://clinicaltrials.gov/ct2/results?term=NCT02182440&Search=Search [Last accessed 20 March 2015]
64. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med 2012;367(24):2322-33
65. Lavoz C, Rodrigues-Diez R, Benito-Martin A. Angiotensin II contributes to renal fibrosis independently of Notch pathway activation. PLoS One 2012;7(7):e40490
66. Bechtel W, McGoohan S, Zeisberg EM, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010;16(5):544-50
67. Sugimoto H, LeBleu VS, Bosukonda D, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 2012;18(3):396-404
68. A study of THR-184 in patients at risk of developing cardiac surgery associated-acute kidney injury (CSA-AKI). Available from: https://clinicaltrials.gov/ct2/results?term=NCT01830920&Search=Search. [Last accessed 20 March 2015]
69. Berger K, Bangen JM, Hammerich L, et al. Origin of regenerating tubular cells after acute kidney injury. Proc Natl Acad Sci USA 2014;111(4):1533-8
70. Wanner N, Hartleben B, Herbach N, et al. Unraveling the role of podocyte turnover in glomerular aging and injury. J Am Soc Nephrol 2014;25(4):707-16
71. Peired A, Angelotti ML, Ronconi E, et al. Proteinuria impairs podocyte regeneration by sequestering retinoic acid. J Am Soc Nephrol 2013;24(11):1756-68
72. Berzal S, Alique M, Ruiz-Ortega M, et al. GSK3, snail, and adhesion molecule regulation by cyclosporine A in renal tubular cells. Toxicol Sci 2012;127(2):425-37
73. Roxanas M, Grace BS, George CR. Renal replacement therapy associated with lithium nephrotoxicity in Australia. Med J Aust 2014;200(4):226-8
74. Bao H, Ge Y, Wang Z, et al. Delayed administration of a single dose of lithium promotes recovery from AKI. J Am Soc Nephrol 2014;25(3):488-500
75. Jesinkey SR, Funk JA, Stallons LJ, et al. Formoterol restores mitochondrial and renal function after ischemia-reperfusion injury. J Am Soc Nephrol 2014;25(6):1157-62
76. Kulkarni OP, Hartter I, Mulay SR, et al. Toll-like receptor 4-induced IL-22 accelerates kidney regeneration. J Am Soc Nephrol 2014;25(5):978-89
77. Doi K, Hu X, Yuen PS, et al. AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int 2008;73(11):1266-74
78. Simmons MN, Subramanian V, Crouzet S, et al. Alpha-melanocyte stimulating hormone analogue AP214 protects against ischemia induced acute kidney injury in a porcine surgical model. J Urol 2010;183(4):1625-9
79. Si J, Ge Y, Zhuang S, et al. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and-independent mechanisms. Kidney Int 2013;83(4):635-46
80. Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004;19(2):348-55
81. Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006;69(10):1806-13
82. Salahudeen AK, Haider N, Jenkins J, et al. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 2008;294(6):F1354-65
83. Souza AC, Volpini RA, Shimizu MH, et al. Erythropoietin prevents sepsis-related acute kidney injury in rats by inhibiting NF-kB and upregulating endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2012;302(8):F1045-54
84. Pallet N, Bouvier N, Legendre C, et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 2010;61(1):71-5
85. Nakazawa Y, Nishino T, Obata Y, et al. Recombinant human erythropoietin attenuates renal tubulointerstitial injury in murine adriamycin-induced nephropathy. J Nephrol 2013;26(3):527-33
86. Eliopoulos N, Zhao J, Forner K, et al. Erythropoietin gene-enhanced marrow mesenchymal stromal cells decrease cisplatin-induced kidney injury and improve survival of allogeneic mice. Mol Ther 2011;19(11):2072-83
87. Liu N, Tian J, Cheng J, et al. Effect of erythropoietin on the migration of bone marrow-derived mesenchymal stem cells to the acute kidney injury microenvironment. Exp Cell Res 2013;319(13):2019-27
88. Coldewey SM, Khan AI, Kapoor A, et al. Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the b-common receptor. Kidney Int 2013;84(3):482-90
89. Patel NS, Kerr-Peterson HL, Brines M, et al. Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Mol Med 2012;18:719-27
90. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361(21):2019-32
91. Shah SV, Rajapurkar MM, Baliga R. The role of catalytic iron in acute kidney injury. Clin J Am Soc Nephrol 2011;6(10):2329-31
92. Lele SS, Mukhopadhyay BN, Mardikar MM, et al. Impact of catalytic iron on mortality in patients with acute coronary syndrome exposed to iodinated radiocontrast-The Iscom Study. Am Heart J 2013;165(5):744-51
93. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149(5):1060-72
94. Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 2014;16(12):1180-91
95. Deferiprone for the prevention of contrast-induced acute kidney injury. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01146925 &Search=Search. [Last accessed 20 March 2015]
96. Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, et al. Deferasirox nephrotoxicity-the knowns and unknowns. Nat Rev Nephrol 2014;10(10):574-86
97. Kohan DE, Pollock DM. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol 2013;76(4):573-9
98. Study of diabetic nephropathy with atrasentan. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01858532&Search=Search [Last accessed 20 March 2015]
99. A study of atrasentan on reducing albuminuria in type 2 diabetic nephropathy treated with renin-angiotensin system inhibitors. Available from: https://clinicaltrials.gov/ct2/results?term=NCT00920764&Search=Search [Last accessed 20 March 2015]
100. Mutig K, Paliege A, Kahl T, et al. Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. Am J Physiol Renal Physiol 2007;293(4):F1166-77
101. Torres VE. Vasopressin antagonists in polycystic kidney disease. Kidney In 2005;68(5):2405-18
102. Yasuda G, Jeffries WB. Regulation of cAMP production in initial and terminal inner medullary collecting ducts. Kidney Int 1998;54(1):80-6
103. Yamaguchi T, Nagao S, Kasahara M, et al. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 1997;30(5):703-9
104. Yamaguchi T, Pelling JC, Ramaswamy NT, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000;57(4):1460-71
105. Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004;10(4):363-4
106. Wang X, Gattone V II, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005;16(4):846-51
107. Wang X, Wu Y, Ward CJ, et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008;19(1):102-8
108. Gattone VH II, Maser RL, Tian C, et al. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 1999;24(3-4):309-18
109. Nagao S, Nishii K, Katsuyama M, et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006;17(8):2220-7
110. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367(25):2407-18
111. Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin in Central America: the case for a Mesoamerican nephropathy. Am J Kidney Dis 2014;63(3):506-20
112. Johnson RJ, Rodriguez-Iturbe B, Roncal-Jimenez C, et al. Hyperosmolarity drives hypertension and CKD-water and salt revisited. Nat Rev Nephrol 2014;10(7):415-20
113. Wesseling C, Crowe J, Hogstedt C, et al. Resolving the enigma of the mesoamerican nephropathy: a research workshop summary. Am J Kidney Dis 2014;63(3):396-404
114. Raines N, González M, Wyatt C, et al. Risk factors for reduced glomerular filtration rate in a Nicaraguan community affected by Mesoamerican nephropathy. MEDICC Rev 2014;16(2):16-22
115. Moreno JA, Sanchez-Niño MD, Sanz AB. A slit in podocyte death. Curr Med Chem 2008;15(16):1645-54
116. Fiorina P, Vergani A, Bassi R, et al. Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol 2014;25(7):1415-29
117. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14(9):931-8
118. Fornoni A, Sageshima J, Wei C. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011;3(85):85ra46
119. Reiser J, von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004;113(10):1390-7
120. Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013;369(25):2416-23
121. Efficacy and safety study of abatacept to treat lupus nephritis. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01714817.&Search=Searchhttps://clinicaltrials.gov/ct2/results?term=NCT01714817.&Search=Search [Last accessed 20 March 2015]
122. Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22(8):1543-50
123. Rituximab in progressive IgA nephropathy. Available from: https://clinicaltrials.gov/ct2/results?term=NCT00498368&Search=Search [Last accessed 20 March 2015]
124. Rituximab to prevent recurrence of proteinuria. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01164098&Search=Search [Last accessed 20 March 2015]
125. Rituximab plus cyclosporine in idiopathic membranous nephropathy. Available from: https://clinicaltrials.gov/ct2/results?term=NCT00977977&Search=Search [Last accessed 20 March 2015]
126. Study of rituximab to treat chronic renal transplant rejection. Available from: https://clinicaltrials.gov/ct2/show/NCT00476164?term=NCT00476164 &rank=1 [Last accessed 20 March 2015]
127. Mathieson PW. Proteinuria and immunity-an overstated relationship? N Engl J Med 2008;359(23):2492-4
128. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355(12):1233-43
129. Manrique J, Cravedi P. Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases. Nefrologia 2014;34(3):388-97
130. El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 2015;65(1):127-30
131. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012;366(12):1163-5
132. Le Quintrec M, Lionet A, Kandel C, et al. Eculizumab for treatment of rapidly progressive c3 glomerulopathy. Am J Kidney Dis 2015;65(3):484-9
133. Cybulsky AV, Quigg RJ, Salant DJ. Experimental membranous nephropathy redux. Am J Physiol Renal Physiol 2005;289(4):F660-71
134. Wang Y, Hu Q, Madri JA, et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996;93(16):8563-8
135. Molitoris BA, Dagher PC, Sandoval RM, et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009;20(8):1754-64
136. Ying Y, Kim J, Westphal SN, et al. Targeted deletion of p53 in the proximal tubule prevents ischemic renal injury. J Am Soc Nephrol 2014;25(12):2707-160
137. Yang L, Besschetnova TY, Brooks CR, et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010;16(5):535-43
138. Kelly KJ, Plotkin Z, Stacey L, et al. P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor. J Am Soc Nephrol 2003;14(1):128-38
139. Thompson JD, Kornbrust DJ, Foy JW, et al. Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Nucleic Acid Ther 2012;22(4):255-64
140. A dose escalation and safety study of I5NP in patients undergoing major cardiovascular surgery. Available from: https://clinicaltrials.gov/ct2/results?term= NCT00554359&Search=Search [Last accessed 20 March 2015]
141. A dose escalation and safety study of I5NP to prevent acute kidney injury (AKI) in patients at high risk of AKI undergoing major cardiovascular surgery (QRK.004). Available from: https://clinicaltrials.gov/ct2/results?term= NCT00683553&Search=Search [Last accessed 20 March 2015]
142. I5NP for prophylaxis of delayed graft function in kidney transplantation. Available from: https://clinicaltrials.gov/ct2/results?term= NCT00802347& Search=Search [Last accessed 20 March 2015]
143. Quark Pharmaceuticals reports favorable results from phase II clinical trial evaluating investigational siRNA QPI-1002. Available from: http://www.quarkpharma.com/QBI-EN/2014/Quark-Pharmaceuticals-Reports-Favorable-Results-from-Phase-II-Clinical-Trial-Evaluating-Investigational-siRNA-QPI-1002/. [Last accessed 20 March 2015]
144. Westenfelder C, Togel FE. Protective actions of administered mesenchymal stem cells in acute kidney injury: relevance to clinical trials. Kidney Int Suppl 2011;1(3):103-6
145. Allogeneic multipotent stromal cell treatment for acute kidney injury following cardiac surgery. Available from: https://clinicaltrials.gov/ct2/results?term= NCT00733876&Search=Search [Last accessed 20 March 2015]
146. A study to evaluate the safety and efficacy of AC607 for the treatment of kidney injury in cardiac surgery subjects. Available from: https://clinicaltrials.gov/ct2/results?term= NCT01602328&Search=Search [Last accessed 20 March 2015]
147. Swaminathan M, Mazer D et al. ACT-AKI: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of AC607 for the Treatment of Acute Kidney Injury in Cardiac Surgery Subjects., ASN kidney week. 2014
148. Akhter S, Ahmad I, Ahmad MZ, et al. Nanomedicines as cancer therapeutics: current status. Curr Cancer Drug Targets 2013;13(4):362-78
149. Lorz C, Benito-Martín A, Boucherot A, et al. The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol 2008;19(5):904-1
150. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361(1):11-21
151. Fresquet M, Jowitt TA, Gummadova J, et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol 2015;26(2):302-13
152. Kao L, Lam V, Waldman M, et al. Identification of the immunodominant epitope region in phospholipase a2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy. J Am Soc Nephrol 2014;26(2):291-301
153. Alvarez-Prats A, Hernández-Perera O, Díaz-Herrera P, et al. Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy. Nephrol Dial Transplant 2012;27(7):2720-33
154. Ruggenenti P, Remuzzi G. Dual RAS blockade-controversy resolved. Nat Rev Nephrol 2013;9(11):640
155. Zoja C, Corna D, Nava V, et al. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol 2013;304(6):F808-19
156. Chin MP, Wrolstad D, Bakris G, et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail 2014;20(12):953-8
157. Carrero JJ, Ortiz A, Qureshi AR, et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009;4(1):110-18
158. Muñoz-García B, Moreno JA, López-Franco O, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2009;29(12):2061-8
159. Sanz AB, Sanchez-Niño MD, Izquierdo MC, et al. TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One 2010;5(1):e8955
160. Moreno JA, Izquierdo MC, Sanchez-Niño MD, et al. The inflammatory cytokines TWEAK and TNFa reduce renal Klotho expression through NFkB. J Am Soc Nephrol 2011;22(7):1315-25
161. Izquierdo MC, Sanz AB, Mezzano S, et al. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int 2012;81(11):1098-107
162. Rayego-Mateos S, Morgado-Pascual JL, Sanz AB, et al. TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation. J Pathol 2013;231(4):480-94
163. Berzal S, González-Guerrero C, Rayego-Mateos S, et al. TNF-related weak inducer of apoptosis (TWEAK) regulates junctional proteins in tubular epithelial cells via canonical NF-kB pathway and ERK activation. J Cell Physiol 2014. [Epub ahead of print]
164. ONTARGET Investigators. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59